---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-003153"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:21:05.310452+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Arbutus reports Q1 net loss $24.5M; imdusiran functionally cures 8 cHBV patients

## Summary
- Net loss $24.5M ($0.13/share) vs $17.9M ($0.10) in Q1 2024; revenue $1.8M vs $1.5M.
- Cash, equivalents & securities $112.7M as of Mar 31, down from $122.6M at Dec 31, 2024.
- Imdusiran combo therapy functionally cured 8 cHBV patients to date; 2 received no interferon.
- AB-101 oral PD-L1 inhibitor achieved 100% receptor occupancy in 11 of 13 healthy subjects at 40mg.
- Moderna U.S. jury trial set for Sep 29, 2025; claim construction for Pfizer/BioNTech expected in 2025.

## SEC filing metadata
- accession: 0001171843-25-003153
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184325003153/0001171843-25-003153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184325003153/f8k_051425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-003153
- JSON: https://secwatch.observer/filing/0001171843-25-003153.json
- Plain text: https://secwatch.observer/filing/0001171843-25-003153.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.